| CAS NO: | 102767-28-2 |
| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 5mg | 电议 |
| 100mg | 电议 |
| Cas No. | 102767-28-2 |
| 别名 | 左乙拉西坦; UCB L059 |
| 化学名 | (2S)-2-(2-oxopyrrolidin-1-yl)butanamide |
| Canonical SMILES | CCC(C(=O)N)N1CCCC1=O |
| 分子式 | C8H14N2O2 |
| 分子量 | 170.21 |
| 溶解度 | DMF: 20 mg/ml,DMSO: 20 mg/ml,Ethanol: 16.7 mg/ml,PBS (pH 7.2): 10 mg/ml |
| 储存条件 | Store at -20℃ |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Levetiracetam (LEV) is a newly developed antiepileptic drug (AED) with a broad spectrum of efficacy against partial and generalized seizures. [1] The mode of action of LEV seems to be different from other AED. Synaptic vesicle protein 2A which can block calcium release from intraneuronal stores is shown to be the binding site of levetiracetam. Thus, it works against the negative modulators of gamma-aminobutyric acid and glycin-gated currents. Moreover, LEV does not have the ablility to induce cytochrome P450 isoenzyme.[2] A study has shown that an oral dose of LEV can’t bind to plasma proteins, while no hepatic metabolism was observed. One-third of the metabolized drug was found to be hydrolyzed and the others were excreted unchanged in the urine.[3] References: |
m.cnreagent.com